Harvard Bioscience (HBIO)

• Market cap: $15.8M
• 1 day: -6.13%
• 5 days: -11.17%
• 1 month: -42.74%
• 3 months: -81.32%
• 6 months: -84.63%
• Year to date: -82.06%
• 1 year: -90.16%
• 5 years: -86.90%
• 10 years: -94.26%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.

Employees: 416

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

36% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 25

23% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 13

1% more funds holding

Funds holding: 94 [Q3] → 95 (+1) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

1.03% less ownership

Funds ownership: 72.04% [Q3] → 71.01% (-1.03%) [Q4]

23% less capital invested

Capital invested by funds: $84.2M [Q3] → $65.1M (-$19.1M) [Q4]

96% less call options, than puts

Call options by funds: $2K | Put options by funds: $51K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4.50 1,136% upside
• Avg. target: $4.50 1,136% upside
• High target: $4.50 1,136% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Benchmark Bruce Jackson 26% 1-year accuracy 12 / 46 met price target

1,136% upside $4.50

Speculative Buy Maintained

24 Mar 2025